Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy 2 years [clinicaltrials_resource:00021e80640d139223721e889a199de5]
The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy 2 years [clinicaltrials_resource:00021e80640d139223721e889a199de5]
The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
Bio2RDF identifier
00021e80640d139223721e889a199de5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:00021e80640d139223721e889a199de5
measure [clinicaltrials_vocabulary:measure]
Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy
time frame [clinicaltrials_vocabulary:time-frame]
description
The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
identifier
clinicaltrials_resource:00021e80640d139223721e889a199de5
title
Tumor metabolic response via FDG-PET at 4 weeks after chemotherapy 2 years
@en
type
label
Tumor metabolic response via F ...... 21e80640d139223721e889a199de5]
@en